DRONTAL CAT TABLETS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

PRAZIQUANTEL, PYRANTEL EMBONATE

Available from:

Bayer Limited

ATC code:

QP52AA51

INN (International Name):

PRAZIQUANTEL, PYRANTEL EMBONATE

Dosage:

Unknown

Pharmaceutical form:

Tablets

Prescription type:

CAM-Companion Animal Medicine

Therapeutic group:

Feline

Therapeutic area:

Praziquantel, combinations

Therapeutic indications:

Endoparasiticide

Authorization status:

Authorised

Authorization date:

1995-09-22

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Drontal Cat Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
White to yellowish scored coated tablet.
The tablet can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of gastrointestinal roundworms and tapeworms:
_Toxocara cati, Toxascaris leonina, Dipylidium caninum, Taenia
taeniaeformis._
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
Not intended for use in kittens less than 6 weeks of age.
Do not use during pregnancy.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Fleas serve as intermediate hosts for one common type of
tapeworm-_Dipylidium caninum_. Tapeworm infestation is
certain to re-occur unless control of intermediate hosts such as
fleas, mice etc is undertaken.
As a precautionary measure to prevent establishment of_ Echinococcus
multilocularis_ in the UK and Ireland, it is
recommended that all dogs and cats entering the country be treated
with praziquantel.
2.1 ACTIVE CONSTITUENTS
MG PER TABLET
Pyrantel Embonate
230.0
Praziquantel
20.0
2.2 RELEVANT CONSTITUENTS OF THE EXCIPIENTS
Titanium Dioxide E171
1.8
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_6_
_2_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 
                                
                                Read the complete document